2402-24-6

Basic information

• Product Name: (3α,5β)-Tetrahydro 11-Deoxycorticosterone 21-Acetate
• Synonyms: (3α,5β)-Tetrahydro 11-Deoxycorticosterone 21-Acetate;LNQFXEKUXJUUMN-LSXNRQBNSA-N
• CAS NO: 2402-24-6
• Molecular Formula: C₂₃H₃₆O₄
• Molecular Weight: 376.52954
• Mol File: 2402-24-6.mol
• Article Data: 3

Chemical Properties

• Melting Point: 173-176 °C
• Boiling Point: 488.5±20.0 °C(Predicted)
• Appearance: /
• Density: 1.111±0.06 g/cm3(Predicted)
• Solubility: Dichloromethane, Ethyl Acetate
• PKA: 15.11±0.70(Predicted)
• CAS DataBase Reference: (3α,5β)-Tetrahydro 11-Deoxycorticosterone 21-Acetate(CAS DataBase Reference)
• NIST Chemistry Reference: (3α,5β)-Tetrahydro 11-Deoxycorticosterone 21-Acetate(2402-24-6)
• EPA Substance Registry System: (3α,5β)-Tetrahydro 11-Deoxycorticosterone 21-Acetate(2402-24-6)

Safety Data

• Hazardous Substances Data: 2402-24-6(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

(3α,5β)-Tetrahydro 11-Deoxycorticosterone 21-Acetate is Tetrahydro 11-Deoxycorticosterone (T293270) derivative. Used in the preparation of steroids with the ability to potentiate GABA-receptor-mediated Cl- uptake into cerebral cortical synaptoneurosomes.

Upstream product

• 4469-03-8 3α-hydroxy-5β-pregnan-20-one 
• 18000-94-7 3α-formyloxy-5β-pregnan-20-one 
• 64-19-7 acetic acid 
• 96553-93-4 21-acetoxy-3α-formyloxy-5β-pregnan-20-one 
• 2402-25-7 21-acetoxy-5β-pregnane-3,20-dione 
• 516-55-2 isopregnanolone 
• 546-67-8 lead(IV) tetraacetate 
• 566-78-9 21-acetoxypregnenolone 

Downstream Products

• 567-03-3 tetrahydrodeoxycorticosterone 
• 567-02-2 (3β,5α)-3,21-dihydroxypregnan-20-one 
• 4131-27-5 21-acetoxy-3β-(toluene-4-sulfonyloxy)-5α-pregnan-20-one 
• 40129-02-0 3β,21-diacetoxy-5α-pregnan-20-one 
• 2402-25-7 21-acetoxy-5β-pregnane-3,20-dione 

Relevant articles and documents

INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS

The present disclosure provides for methods of treating or preventing a cardiovascular disorder and/or a related pulmonary disorder in a subject. In certain embodiments, the method comprises administering a therapeutically effective amount of an inhibitor of Glucose-6-phosphate dehydrogenase (G6PD), or a pharmaceutically acceptable salt, non-salt amorphous form, solvate, poly-morph, tautomer or prodrug thereof.

METHODS, COMPOSITIONS, AND COMPOUNDS FOR ALLOSTERIC MODULATION OF THE GABA RECEPTOR BY MEMBERS OF THE ANDROSTANE AND PREGNANE SERIES

Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, insomnia and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid receptor-chloride ionophore (GR) complex.